OphtAI's software analyzes retina fundus photos to detect early signs of diabetic retinopathy, glaucoma, and AMD. It aims to address the public health issue of screening for these diseases, which are leading causes of blindness. The software allows for photo quality control, lesion mapping, and severity assessment, providing recommendations for further action. OphtAI's service is a CE Cat IIa medical device and can be used by non-experts during patient consultations. The company has partnered with Paris Hospitals and an AI research laboratory to develop its technology. OphtAI plans to expand its capabilities to detect other eye conditions in the future.